We found that the presence of diploid karyotype (p = 0.006), IDH2 mutations (p < 0.001), and intensive therapy (p < 0.001) were correlated with longer survival, while the presence of TP53 mutations (p < 0.001), complex karyotype (p < 0.001), MDS cytogenetics (p < 0.0001), older age (p < 0.001), and MF 2–3 ( p < 0.001) were correlated with worse survival. Here, IDH2 is linked to myelodysplastic syndrome.